Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Abbott Laboratories (Pakistan) Limited

Market Cap 93.44B 336M 293M 271M 254M 476M 31.7B 479M 3.22B 1.25B 15.6B 1.26B 1.23B 54.17B P/E 2024
23.2x
P/E 2025 -
Enterprise Value 93.44B 336M 293M 271M 254M 476M 31.7B 479M 3.22B 1.25B 15.6B 1.26B 1.23B 54.17B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
20.04%
Yield 2024 *
-
Yield 2025 3.81%
1 day-2.47%
1 week+7.38%
Current month+6.65%
1 month+13.06%
3 months+2.56%
6 months-9.86%
Current year-9.11%
1 week 900
Extreme 900
990
1 month 861.3
Extreme 861.3
990
Current year 821
Extreme 821
1,274
1 year 821
Extreme 821
1,304
3 years 330
Extreme 330
1,310
5 years 330
Extreme 330
1,310
10 years 302.1
Extreme 302.1
1,310
Manager TitleAgeSince
Chief Executive Officer - 2016-03-31
Director of Finance/CFO - 2019-10-31
Chief Operating Officer - 2024-05-31
Director TitleAgeSince
Director/Board Member - 2009-02-28
Director/Board Member - 2014-06-03
Chairman - 2022-05-29
Change 5-day change 1-year change 3-year change Capi.($)
-2.47%+7.38%+0.10%+154.84% 336M
-1.21%-3.04%+44.03%+143.07% 980B
-2.48%-5.18%+52.47%+39.15% 550B
-2.14%-4.94%+16.83%+57.08% 382B
+0.25%-3.09%+23.33%+16.04% 316B
+0.61%-1.69%+27.35%+13.73% 272B
+0.22%-3.10%+24.67%+30.49% 268B
+4.59%+1.98%-38.43%-46.26% 199B
-1.19%-4.95%+16.68%+47.69% 182B
-1.35%-1.46%+14.06%+59.26% 154B
Average -0.52%-2.39%+18.11%+51.51% 330.27B
Weighted average by Cap. -0.78%-3.68%+29.49%+63.32%

Financials

2024 2025
Net sales 68.18B 245M 214M 198M 185M 347M 23.12B 350M 2.35B 910M 11.38B 920M 900M 39.52B 75.4B 271M 236M 219M 205M 384M 25.57B 387M 2.6B 1.01B 12.59B 1.02B 996M 43.71B
Net income 5.23B 18.82M 16.41M 15.19M 14.22M 26.67M 1.78B 26.84M 180M 69.86M 874M 70.63M 69.11M 3.03B 7.97B 28.64M 24.97M 23.12M 21.65M 40.6M 2.7B 40.84M 274M 106M 1.33B 107M 105M 4.62B
Net Debt - -
Logo Abbott Laboratories (Pakistan) Limited
Abbott Laboratories Pakistan Limited is engaged in the manufacture, import and marketing of branded generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. The Company operates through four segments: Pharmaceutical, Nutritional, Diagnostic, and Others. It offers treatment options for a number of areas, including the digestive system, heart health, women’s health, respiratory illness, central nervous system/pain and influenza vaccines. Its nutritional brands include Similac, PediaSure, Pedialyte, Ensure, and Glucerna. It offers tests and diagnostic tools, medical diagnostic instruments, automation and informatics solutions for hospitals, reference labs, blood centers, emergency departments, physician offices and clinics. The Company’s easy-to-use test strips require only tiny blood samples while its meters provide results and reports.
Employees
1,380
Date Price Change Volume
26-06-19 954.49 -2.47% 24,286
26-06-18 978.67 +2.87% 37,721
26-06-17 951.37 +0.34% 48,045
26-06-16 948.13 +2.58% 25,279
26-06-15 924.24 +3.98% 61,357
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
954.49
Average target price
-

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ABOT Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!